JMS Co.,Ltd.
Stock Price Chart
2026/11/06 19:48 UpdatedPrice Trend
2026/11/06 19:48 UpdatedPrice & Trading Details
2026/11/06 19:48 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/11/01Dividend History
Updated 2026/11/01| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥17 | 0.0% |
| 2025 | ¥17 | 0.0% |
| 2024 | ¥17 | 0.0% |
| 2023 | ¥17 | 0.0% |
| 2022 | ¥17 | - |
Financial Performance
2026/11/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥63,740M | ¥65,292M | ¥69,749M | ¥65,845M |
| Gross Profit | ¥14,594M | ¥14,094M | ¥15,924M | ¥15,355M |
| Operating Income | ¥725M | -¥268M | ¥873M | ¥382M |
| Pretax Income | ¥787M | ¥365M | ¥901M | ¥39M |
| Net Income | ¥281M | -¥36M | ¥89M | -¥783M |
| EPS | ¥11.50 | -¥1.48 | ¥3.63 | -¥31.92 |
| Operating Margin | 1.14% | -0.41% | 1.25% | 0.58% |
| Balance Sheet | ||||
| Total Assets | ¥74,407M | ¥84,709M | ¥81,432M | ¥83,067M |
| Total Equity | ¥38,530M | ¥40,572M | ¥40,834M | ¥41,730M |
| Total Liabilities | ¥35,877M | ¥44,137M | ¥40,598M | ¥41,337M |
| Cash | ¥6,329M | ¥10,308M | ¥5,511M | ¥7,721M |
| Interest-bearing Debt | ¥19,748M | ¥26,923M | ¥24,550M | ¥28,006M |
| Equity Ratio | 51.78% | 47.90% | 50.14% | 50.24% |
| D/E Ratio | 0.51 | 0.66 | 0.60 | 0.67 |
| Cash Flow | ||||
| Operating CF | ¥2,485M | ¥3,140M | ¥1,467M | ¥1,584M |
| Investing CF | -¥3,691M | -¥4,239M | -¥3,132M | -¥2,250M |
| Financing CF | ¥525M | ¥4,775M | -¥3,186M | ¥2,687M |
| Free CF | -¥1,071M | ¥498M | -¥1,573M | -¥1,075M |
| Efficiency | ||||
| ROE | 0.73% | -0.09% | 0.22% | -1.88% |
| ROA | 0.38% | -0.04% | 0.11% | -0.94% |
Latest IR Information
-
Fiscal Year Ending March 2027 Second Quarter (Interim) Financial Summary [Japanese GAAP] (Consolidated)
Revenue of 32,391 million yen (Year-over-Year +0.5%), contributing to operating profit turning positive at 9 million yen. Ordinary loss was 145 million yen, and interim net loss attributable to owners of parent was 262 million yen. Full-year forecasts were revised:...
Read more -
JMS Co.,Ltd. PRESS RELEASE - Notice Regarding Differences Between Forecasts and Actual Results for the Interim Consolidated Fiscal Period for the Fiscal Year Ending March 2027 and Revision of Full-Year Consolidated Earnings Forecast
Net sales for the interim period exceeded the previous forecast, but operating income, ordinary income, and net income attributable to owners of parent for the interim period fell short. The full-year forecast is expected to be revised upward for net...
Read more -
Overview of Consolidated Financial Results for the Second Quarter of Fiscal Year Ending March 2027
Net sales were 32,391 million yen, up 0.5% year-over-year. Operating income was 9 million yen, ordinary loss was -145 million yen, and net loss attributable to owners of parent was -262 million yen. By region there were fluctuations in Japan,...
Read more -
Share Buyback of Restricted Stock-Based Compensation｜July 16, 2026
JMS resolved to dispose of 20,521 treasury shares at 468 yen on August 5, 2026, and allocate them as part of stock-based compensation with restrictions on transfer to five directors and seven executive officers. The transfer restriction period is set...
Read more
Latest News (5 items)
Company Information
About
JMS Co.,Ltd. engages in the manufacture, sale, export, and import of medical devices and pharmaceuticals in Japan, Asia, North America, Europe, China, South Korea, Thailand, and internationally. It offers infusion and nutrition solutions, which includes needless access port, closed drug mixing and infusion system, infusion pump, and oral and enteral nutrition system for treatment and laboratory testing; and dialysis solutions including dialysis equipment for hemodialysis, peritoneal dialysis solution, and APD equipment that automatically performs the injection and discharge of peritoneal dialysis solution, as well as offers hemodialysis machines. It also provides surgical treatment solution comprising products that are used in cardiac surgery and cardiovascular internal medicine, such as membrane oxygenator and cardiopulmonary blood pump systems. In addition, the company offers blood management and cell therapy solutions, which includes serum collection sets and blood bags. Further, it provides logistics and other equipment; and offers maintenance works and sanatorium services. The company was incorporated in 1947 and is headquartered in Hiroshima, Japan.
